



2025 GNIPST BULLETIN

(Pharmacy)

Volume-2, Issue- 2

Special Attraction Page



an NGO working on
uplifting underprivileged children



GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

1	Message from Director and Principal	1
2	Recent Researches	2
3	New Drug Approvals	3
4	Clinical Trial News	4
5	Disease Outbreak News	5
6	Campus News	6
7	Special Pages	7-8
8	Game Time	9-10





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings to all of you. May this year bring you abundant joy, success, and fulfillment. At our esteemed institution, we remain steadfast in our commitment to fostering an environment that champions academic


excellence, innovation, and holistic development. With a dedicated focus on the pursuit of Pharmaceutical Sciences, we continue to nurture inquisitive minds, inspire critical thinking, and equip our students with the skills necessary for their success.

As we step into 2025, we are excited to continue growing, evolving, and upholding our mission to provide top-quality education, while promoting research and innovation. We are deeply grateful for your ongoing support, involvement, and collaboration with Guru Nanak Institute of Pharmaceutical Science and Technology.

Prof. (Dr.) Abhijit Sengupta

MESSAGE FROM HONORABLE PRINCIPAL

I extend my heartfelt wishes to all our students, faculty, staff, and partners. May this year bring you abundant health, happiness, and success. Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) has consistently demonstrated its dedication to delivering high-quality pharmacy education.



As we approach 2025, our commitment to achieving excellence in both academic and professional development remains unwavering. Founded in 2005 and recognized by the Pharmacy Council of India (PCI), GNIPST stands as a leader in pharmacy education within West Bengal. We take immense pride in being the pioneering pharmacy institution in the region to attain accreditation from both NAAC and NBA. Furthermore, GNIPST has earned recognition as an NIRF-ranked pharmacy institute, achieving an impressive 74th position in 2024.

We believe that the values, traditions, and educational facilities at GNIPST, along with our unwavering focus on innovation and research, will continue to guide our students to greater achievements. As we move forward, we invite those passionate about pharmacy to choose this field as a career and join us for an academically enriching and rewarding experience.

Here's to a successful and inspiring 2025, filled with opportunities to grow, learn, and excel."

Prof. (Dr.) Lopamudra Datta



RECENT RESEARCHES



Guinea eliminates human African trypanosomiasis as a public health problem

MORE INFO

www.who.int/

The World Health Organization (WHO) congratulates Guinea for eliminating the gambiense form of human African trypanosomiasis as a public health problem. This form of human African trypanosomiasis, the only type transmitted in Guinea, is the first neglected tropical disease to be eliminated in the country. The news marks an important achievement in this public health field on the eve of the world Neglected Tropical Diseases Day, marked on 30 January. “Today’s announcement is both a testament to the global progress against neglected tropical diseases and a beacon of hope for nations still battling human African trypanosomiasis,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

WHO and partners enable access to candidate vaccine and treatments for outbreak of Sudan Ebola virus disease in Uganda

MORE INFO

www.who.int/

WHO and partners have immediately boosted their support to the Ugandan government’s response to an outbreak of Sudan virus disease outbreak (SVD, part of the Ebola family), including by facilitating access to a candidate vaccine and candidate treatments. The first 2160 doses of the vaccine candidate and the treatments are already in Kampala, Uganda, as they were prepositioned as part of outbreak preparedness. The vaccine trial processes underway include orientation of the research teams on the trial procedures, and logistics arrangements. Research teams have been deployed to the field to work along with the surveillance teams as approvals are awaited. The candidate vaccine and the candidate treatments (a monoclonal antibody and an antiviral) are being made available through clinical trial protocols, which will make it possible to further document their efficacy and safety.

Georgia certified malaria-free by WHO.

MORE INFO

www.who.int/

Following a nearly century-long effort, Georgia has been certified malaria-free by the World Health Organization (WHO). With today’s announcement, Georgia joins the ranks of 45 countries and 1 territory that have achieved this milestone. “Today we congratulate the people of Georgia for their decades of targeted and sustained actions to eliminate malaria, one of the world’s leading killers,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Georgia’s commitment and success gives us hope that a malaria-free world is possible.”

FDA

NEW DRUG APPROVALS

January, 2025

Datroway (datopotamab deruxtecan-dlnk) Lyophilized Powder for Injection

- Company: AstraZeneca and Daiichi Sankyo
- Date of Approval: January 17, 2025
- Treatment for: Breast Cancer



Grafapex (treosulfan) Lyophilized Powder for Injection

- Company: Medexus Pharmaceuticals Inc.
- Date of Approval: January 21, 2025
- Treatment for: Stem Cell Transplant Conditioning



Avtozma (tocilizumab-anoh) Injection

- Company: Celltrion USA
- Date of Approval: January 24, 2025
- Treatment for: Rheumatoid Arthritis, Giant



Symbravo (meloxicam and rizatriptan) Tablets – formerly AXS-07

- Company: Axsome Therapeutics, Inc.
- Date of Approval: January 30, 2025
- Treatment for: Migraine



Journavx (suzetrigine) Tablets – formerly VX-548

- Company: Vertex Pharmaceuticals Incorporated
- Date of Approval: January 30, 2025
- Treatment for: Pain



Onapgo (apomorphine hydrochloride) Infusion Device – formerly SPN-830

- Company: Supernus Pharmaceuticals, Inc.
- Date of Approval: February 3, 2025
- Treatment for: Parkinson's Disease



Emblaveo (avibactam and aztreonam) Lyophilized Powder for Injection

- Company: AbbVie Inc.
- Date of Approval: February 7, 2025
- Treatment for: Intraabdominal Infection



<https://www.drugs.com/newdrugs.html>



CLINICAL TRIAL NEWS



01.

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

CAMBRIDGE, Mass.-- January 21, 2025 (BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, an investigational antisense oligonucleotide (ASO) targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

02.

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain.

MONMOUTH JUNCTION, NJ, January 22, 2025 - Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-1 pivotal Phase 3 clinical trial evaluating cebranopadol, an investigational therapy, for the treatment of moderate-to-severe acute pain in patients following abdominoplasty surgery. These results add to the growing body of data underscoring the promising efficacy and safety profile of cebranopadol, a first-in-class pain therapy involving dual-nociceptin/orphanin FQ peptide (NOP) receptor and μ -opioid peptide (MOP) receptor (dual-NMR) agonism.

03.

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology

SPRING HOUSE, Pa., (January 23, 2025) - Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad population of antibody positive (anti-AChR+, anti-MuSK+, anti-LRP4+) adults with generalized myasthenia gravis (gMG).¹ The Vivacity-MG3 study met its primary endpoint demonstrating statistically significant and clinically meaningful improvement over 24 weeks in the MG-ADLa score.¹ Nipocalimab had a tolerable safety profile, with adverse events leading to discontinuation rates similar to placebo (5.1% with nipocalimab vs. 7.1% with placebo).

04.

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Bagsværd, Denmark, 24 January 2025 - Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

05.

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to MB-105, the company's first-in-class CD5-targeted CAR-T cell therapy, for the treatment of relapsed / refractory CD5-positive T-cell lymphoma.

06.

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy.

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 30 January 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA).

MORE INFORMATION



https://www.drugs.com/clinical_trials_archive/january-2025.html



DISEASE OUTBREAK NEWS (DONS)

January, 2025

Trends of acute respiratory infection, including human metapneumovirus, in the Northern Hemisphere

7 January 2025

Situation at a glance

In many countries of the Northern Hemisphere, trends in acute respiratory infections increase at this time of year. These increases are typically caused by seasonal epidemics of respiratory pathogens such as seasonal influenza, respiratory syncytial virus (RSV), and other common respiratory viruses, including human metapneumovirus (hMPV), as well as mycoplasma pneumoniae. Many countries conduct routine surveillance for acute respiratory infections and common respiratory pathogens. Currently, in some countries in the temperate Northern hemisphere, influenza-like illness (ILI) and/or acute respiratory infection (ARI) rates have increased in recent weeks and are above baseline levels, following usual seasonal trends. Seasonal influenza activity is elevated in many countries in the Northern hemisphere. Where surveillance data is available, trends in RSV detections currently vary by region with decreases reported in most regions except in North America. Recently, there has been interest in hMPV cases in China including suggestions of hospitals being overwhelmed. hMPV is a common respiratory virus found to circulate in many countries in winter through to spring, although not all countries routinely test and publish data on trends in hMPV. While some cases can be hospitalized with bronchitis or pneumonia, most people infected with hMPV have mild upper respiratory symptoms similar to the common cold and recover after a few days. Based on data published by China, covering the period up to 29 December 2024, acute respiratory infections have increased during recent weeks and detections of seasonal influenza, rhinovirus, RSV, and hMPV, particularly in northern provinces of China have also increased. The observed increase in respiratory pathogen detections is within the range expected for this time of year during the Northern hemisphere winter. In China, influenza is the most commonly detected respiratory pathogen currently affecting people with acute respiratory infections. WHO is in contact with Chinese health officials and has not received any reports of unusual outbreak patterns. Chinese authorities report that the health care system is not overwhelmed and there have been no emergency declarations or responses triggered. WHO continues to monitor respiratory illnesses at global, regional and country levels through collaborative surveillance systems, and provides updates as needed.

MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON547>

Zika virus disease - India

29 January 2025


Situation at a glance

Between 1 January and 31 December 2024, a cumulative total of 151 Zika virus disease (ZVD) cases were reported from three states in India (Gujarat, Karnataka, and Maharashtra states). Maharashtra State reported a cumulative total of 140 ZVD cases through the Integrated Disease Surveillance Programme (IDSP). Additionally, Karnataka and Gujarat states reported ten and one cases, respectively, in 2024. As of 31 December 2024, no cases of microcephaly and/or Guillain-Barre syndrome (GBS) associated with this outbreak have been reported. Zika virus (ZIKV) is transmitted to humans by the bite of an infected Aedes mosquito. Zika virus is also transmitted from mother to fetus during pregnancy, as well as through sexual contact, transfusion of blood and blood products, and possibly through organ transplantation. There is no specific treatment available for Zika virus infection or disease.

MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON548>

CAMPUS NEWS



...to share that our very own
...Chowdhury, a distinguished faculty
...research and professional interests of
...Biotechnology, Bioprocess and
...Higher Studies to the renowned newspaper Ajkal

Sopan. In his well-articulated piece, Dr. Chowdhury highlights the vast potential of biotechnology in shaping the future of scientific research, innovation, and academic pursuits. His expertise and perspective offer invaluable insights for students and professionals looking to dive into the dynamic field of biotechnology. A huge congratulations to Dr. Chowdhury for this accomplishment, and we encourage everyone to read his thought-provoking article in Ajkal Sopan. It's a must-read for those passionate about advancing their studies and careers in the exciting world of biotechnology.



GNIPST was excited to announce a Six-day Faculty Development Program on Computer Aided Drug Design (CADD) from 03.02.2025 to 08.02.2025. This program aims to enhance knowledge and skills in cutting-edge drug design techniques.



On 4th February 2025, The Social Welfare Club of GNIPST is pleased to announce a National Awareness Seminar on the vital topic of Radiotherapy in the Management of Oral Cancer.



We are thrilled to announce that two of our talented B.Pharm students, Arijit Seni and Sabir Hossain, from the Class of 2025, have been successfully placed at Rajasthan Aushdhalaya Pvt. Ltd. Their hard work, dedication, and commitment to excellence have paid off, and we couldn't be prouder of them! This achievement is a testament to their perseverance and the quality education they've received at our institution.



Arijit Seni

Sabir Hossain

GNIPST celebrated Saraswati Puja on 3rd February 2025 at the GNIPST campus with great enthusiasm and devotion. The campus was beautifully decorated, creating a serene atmosphere for the occasion. Students, faculty, and staff gathered to offer prayers to Goddess Saraswati, the deity of knowledge, music, and arts. The event included traditional rituals, cultural performances, and aarti, creating a vibrant and spiritual ambiance. The celebration fostered a sense of unity and reverence within the GNIPST community, promoting both academic and cultural values. The Puja was a memorable experience for everyone involved.



MORE INFORMATION

www.gnipst.ac.in

SARASWATI PUJA IN BENGAL: A CELEBRATION OF KNOWLEDGE AND WISDOM

Saraswati Puja, dedicated to Goddess Saraswati, is one of the most cherished festivals in Bengal, celebrated with great devotion, especially in schools, colleges, and households. Observed on Vasant Panchami, this festival marks the arrival of spring and is considered an auspicious day for learning.

GNIPST in collaboration with JIS Group organized an event called “Shera Schooler Saraswati” where 35 schools and colleges of different districts participated in this event to showcase their various innovative thought process of decorating pandals and schools or college premises. The selected judges for respective school and colleges examine their decoration and Saraswati idol and appreciate their work by giving them a memento.

Some Gilpin's of the “Shera Schooler Saraswati”



ওঁ সরস্বতী মহাভাগে বিদ্যে কমললোচনে।
 বিশ্বরূপে বিশালাক্ষি বিদ্যাং দেহি নমস্তুতে॥



My journey with Tollygunge Ramdhanu Social Welfare Society has been one of resilience, compassion, and unwavering determination. What began during the pandemic as a simple act of distributing food, books, and colors to street children soon turned into a lifelong mission. Watching their eager faces as they held books and color pencils made me realize that these children deserved more than just temporary relief — they deserved education, dignity, and hope. With my daughter by my side, I started visiting them regularly, teaching them whatever I could.



The challenges were immense. For years, we conducted classes sitting on the pavement, battling the scorching sun, rains, and societal indifference. There were moments of doubt, but I knew giving up was not an option.



Empowering Dreams: The Journey of "Randhanu: THE COLOR OF HOPE" an NGO run by Mitrobinoda Ghosh

After a long battle, we finally secured a shelter home in Kolkata, a place where the children could learn, play, and dream without fear. In the rural village of Murgaboni, we continued our work, focusing on education and vocational training for older girls, empowering them to break free from the cycle of poverty and dependence.




Projects like Colour of Hope and Hopes and Hues became symbols of transformation, offering children not just knowledge but life skills that nurtured their confidence. Seeing a child move from street life to a classroom, from despair to creativity, has been the greatest reward. This journey has taught me that true change takes time, patience, and endless love. Every challenge has been worth it because, in the end, we are lighting lives — turning margins into miracles one step at a time.




foundation.ramdhanu@gmail.com



GNIPST GAME TIME



Crossword PH-4



Across:

2. Vaccines for cervical cancer.
4. Doctor specializing in heart health
5. Bony structure safeguarding the heart and lungs.

Down:

1. Organ that removes toxin from the body.
3. This vitamin is produced from sunlight and crucial for bone strengthening.

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



SCAN
ME

or

CLICK
HERE

GNIPST GAME TIME



4

Answer for Rearrange the words (Drug names)

1. Aceclofenac
2. Amoxicillin
3. Azithromycin
4. Atropine
5. Acyclovir

Cheers to the Victor!

Volume -2, Issue -1



Debanjan Bhattacharya

B.Pharm, 3rd Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

Correct answers received from them also:

1. Tulika Das
2. Dr. Sanchari Bhattacharya (Faculty Member)
3. Banisha Mitra
4. Neha Mondal
5. Rupam Dalal

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamudra Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com